Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   MYLAN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-23
MYLAN
Dec-18
AUROBINDO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7153,967-   
Low Rs3972,184-   
Sales per share (Unadj.) Rs424.21,825.4-  
Earnings per share (Unadj.) Rs32.949.6-  
Cash flow per share (Unadj.) Rs54.1391.3-  
Dividends per share (Unadj.) Rs3.000-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs458.11,974.7-  
Shares outstanding (eoy) m585.94514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.31.7 77.8%   
Avg P/E ratio x16.962.0 27.2%  
P/CF ratio (eoy) x10.37.9 130.7%  
Price / Book Value ratio x1.21.6 77.9%  
Dividend payout %9.10-   
Avg Mkt Cap Rs m325,7531,582,214 20.6%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m35,2230-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m248,554939,158 26.5%  
Other income Rs m2,9060-   
Total revenues Rs m251,460939,158 26.8%   
Gross profit Rs m37,070243,019 15.3%  
Depreciation Rs m12,446175,847 7.1%   
Interest Rs m1,40545,170 3.1%   
Profit before tax Rs m26,12522,002 118.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,849-3,500 -195.7%   
Profit after tax Rs m19,27725,502 75.6%  
Gross profit margin %14.925.9 57.6%  
Effective tax rate %26.2-15.9 -164.8%   
Net profit margin %7.82.7 285.6%  
BALANCE SHEET DATA
Current assets Rs m214,599524,425 40.9%   
Current liabilities Rs m114,938382,364 30.1%   
Net working cap to sales %40.115.1 265.1%  
Current ratio x1.91.4 136.1%  
Inventory Days Days2184 24.7%  
Debtors Days Days6693 70.3%  
Net fixed assets Rs m176,668182,181 97.0%   
Share capital Rs m586500 117.2%   
"Free" reserves Rs m267,8130-   
Net worth Rs m268,3991,015,998 26.4%   
Long term debt Rs m6,1901,096,588 0.6%   
Total assets Rs m392,1252,725,301 14.4%  
Interest coverage x19.61.5 1,317.8%   
Debt to equity ratio x01.1 2.1%  
Sales to assets ratio x0.60.3 183.9%   
Return on assets %5.32.6 203.4%  
Return on equity %7.22.5 286.1%  
Return on capital %10.03.2 315.3%  
Exports to sales %33.70-   
Imports to sales %15.30-   
Net fx Rs m44,0360-   
CASH FLOW
From Operations Rs m23,868195,157 12.2%  
From Investments Rs m-39,778-100,875 39.4%  
From Financial Activity Rs m18,144-90,916 -20.0%  
Net Cashflow Rs m2,2981,617 142.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare AUROBINDO PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: ALCHEMIST LIMITED  LACTOSE INDIA  FREDUN PHARMA  NORRIS MEDICINES  ZENOTECH LABS  



Today's Market

Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine(10:30 am)

Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.